Sanofi Reports Positive Late-Stage Results for New mRNA Respiratory Vaccine
Researchers at Sanofi's Lyon facility have announced successful late-stage clinical trial outcomes for a multivalent respiratory vaccine, strengthening the company's position in advanced vaccine development.